Back to results
US 12,109,269 B2Granted
Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
AssigneeLoyola University of Chicago
InventorsDaniel Paul Becker, Marlon Ray Lutz, Jr.
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.
Claims18
A compound having a structure of Formula (I), or a pharmaceutically acceptable salt thereof:
- wherein
- m is 1;
- n is 1;
- W1 and W2 are each absent;
- X is aryl;
- Y is O or C1-2alkylene-O;
- Z is NR1;
- R1 is C1-6alkylene-CB;
- C1-6alkylene-C3-8heteroaryl-C1-6alkylene-CB, CH(C1-3alkylene-C3-8heteroaryl-CB)2, C1-4alkylene-CH(C1-3alkylene-C3-8-heteroaryl-CB)2, CH(C1-3alkylene-C3-8heteroaryl-C1-6alkylene- CB)2, C1-4alkylene-CH(C1-3alkylene-C3-8 heteroaryl-C1-6alkylene-CB)2, C(C1-3alkylene-C3-8-heteroaryl-CB)3, C1-4alkylene- C(C1-3alkylene-C3-8-heteroaryl-CB)3, C(C1-3alkylene-C3-8-heteroaryl-C1-6alkylene-CB)3, or C1-4alkylene-C(C1-3alkylene-C3-8-heteroaryl-C1-6alkylene-CB)3;
- R2 is aryl-R4 or C1-2alkylene-aryl-R4;
- R3 is H;
- R4 is OC1-6alkyl substituted with halo or C1-6alkylene-OC1-6alkyl substituted with halo;
- and
- CB is carborane,
- wherein C3-8heteroaryl includes 1, 2, or 3 heteroatoms selected from the group consisting of N, O, and S.
12 more elements
A tert-butyldimethylsilyl ether propyl azido carborane compound having a structure:
Dependencies are inferred from the claim text.